Clinical study of tolvaptan combined with Niaoduqing granule in the treatm ent of nephrotic syndrome

Objective To analyze the effect of tolvaptan combined with Niaoduqing granule on improving renal function, blood lipid, blood coagulation and quality of life in patients with nephrotic syndrome. Methods From March 2016 to March 2018, 70 patients with nephrotic syndrome in our hospital were divided into two groups according to the method of random number table. Thirty-five patients in the control group were treated with tovaptan, and 35 patients in the observation group were treated with tolvaptan and Niaoduqing granules. The renal function, blood lipid, coagulation index and quality of life of the two groups were compared before and after treatment. Results After treatment, Scr[(73.16±8.82) μmol/L], BUN[(6.52±0.50) mmol/L] and 24-hour urine protein quantity[(1.21±0.44) g] in the observation group were significantly lower than those in the control group[(84.36±9.68) μmol/L,(7.28±0.67) mmol/L and(1.89±0.58) g], and ALB(39.77±4.45) g/L was significantly higher than that in the control group(34.72±4.20) g/L. After treatment, TG, TC, D-D levels of the two groups were significantly lower than before treatment. FIB of the observation group was significantly lower than before treatment, and TG, TC, D-D, FIB of the observation group were significantly lower than that in the control group(all P<0.05). The quality of life scores of the observation group were significantly higher than that in the control group(all P<0.05). Conclusion The clinical effect of tolvaptan combined with Niaoduqing granules in the treatment of nephrotic syndrome is significant, which can effectively improve the renal function, improve the blood lipid and coagulation indexes, and improve the quality of life of patients.